Literature DB >> 33567045

Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.

Juliana Goldbaum Crescente1,2, Alessandra Dellavance3,4, Marcio Augusto Diniz5, Flair Jose Carrilho1, Luis Eduardo Coelho de Andrade3,4, Eduardo Luiz Rachid Cançado1,2.   

Abstract

OBJECTIVES: To determine the frequency of the antineutrophil cytoplasmic antibodies (ANCA), antiproteinase-3 and antimyeloperoxidase, in primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD+ or IBD-) and in different types of autoimmune hepatitis (AIH). Additionally, to verify the agreement between ANCA patterns by indirect immunofluorescence and their antigenic specificities by ELISA.
METHODS: For this study, 249 patients were enrolled (42 PSC/IBD+; 33 PSC/IBD-; 31 AIH type-1; 30 AIH type-2; 31 AIH type-3; 52 primary biliary cirrhosis; 30 healthy controls) whose serum samples were tested for ANCA autoantibodies.
RESULTS: There were fewer female subjects in the PSC/IBD- group (p=0.034). Atypical perinuclear-ANCA was detected more frequently in PSC/IBD+ patients than in PSC/IBD- patients (p=0.005), and was significantly more frequent in type-1 (p<0.001) and type-3 AIH (p=0.012) than in type-2 AIH. Proteinase-3-ANCA was detected in 25 samples (only one with cytoplasmic-ANCA pattern), and more frequently in PSC/IBD+ than in PSC/IBD- patients (p=0.025). Myeloperoxidase-ANCA was identified in eight samples (none with the perinuclear-ANCA pattern). Among the 62 reactive samples for atypical perinuclear-ANCA, 13 had antigenic specific reactions for proteinase-3 and myeloperoxidase.
CONCLUSIONS: PSC/IBD+ differed from PSC/IBD- in terms of sex and proteinase 3-ANCA and atypical perinuclear-ANCA reactivity, the latter of which was more frequently detected in type-1 and type-3 AIH than in type-2 AIH. There was no agreement between ANCA patterns and antigenic specificities in IBD and autoimmune liver diseases, which reinforces the need for proteinase-3 and myeloperoxidase antibody testing.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33567045      PMCID: PMC7847259          DOI: 10.6061/clinics/2021/e2228

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  30 in total

1.  Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.

Authors:  Diego Vergani; Fernando Alvarez; Francesco B Bianchi; Eduardo L R Cançado; Ian R Mackay; Michael P Manns; Mikio Nishioka; Edward Penner
Journal:  J Hepatol       Date:  2004-10       Impact factor: 25.083

2.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  F Seibold; P Weber; R Klein; P A Berg; K H Wiedmann
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

3.  Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis.

Authors:  D Zauli; S Ghetti; A Grassi; C Descovich; F Cassani; G Ballardini; L Muratori; F B Bianchi
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

4.  PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis.

Authors:  Michael Mahler; Jan Damoiseaux; Vera Ballet; Doreen Dillaerts; Chelsea Bentow; Jan-Willem Cohen Tervaert; Daniel Blockmans; Guy Boeckxstaens; Javier Aguilera-Lizarraga; Elena Csernok; Severine Vermeire; Xavier Bossuyt
Journal:  Clin Chem Lab Med       Date:  2017-11-27       Impact factor: 3.694

5.  Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays.

Authors:  Jan Damoiseaux; Elena Csernok; Niels Rasmussen; Frank Moosig; Pieter van Paassen; Bo Baslund; Pieter Vermeersch; Daniel Blockmans; Jan-Willem Cohen Tervaert; Xavier Bossuyt
Journal:  Ann Rheum Dis       Date:  2016-08-01       Impact factor: 19.103

Review 6.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

7.  Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis.

Authors:  S Hardarson; D R Labrecque; F A Mitros; G A Neil; J A Goeken
Journal:  Am J Clin Pathol       Date:  1993-03       Impact factor: 2.493

8.  Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Kirsten M Boberg; Eli Taraldsrud; Mette Vesterhus; Maria Boyadzhieva; Inger Camilla Solberg; Erik Schrumpf; Morten H Vatn; Benedicte A Lie; Øyvind Molberg; Tom H Karlsen
Journal:  Liver Int       Date:  2016-09-13       Impact factor: 5.828

9.  Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.

Authors:  D S Bansi; K A Fleming; R W Chapman
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

10.  Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases.

Authors:  C Claise; C Johanet; Y Bouhnik; N Kapel; J C Homberg; R Poupon
Journal:  Liver       Date:  1996-02
View more
  1 in total

1.  Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study.

Authors:  Guillermo Muñoz-Sánchez; Albert Pérez-Isidro; Iñaki Ortiz de Landazuri; Antonio López-Gómez; Luz Yadira Bravo-Gallego; Milagros Garcia-Ormaechea; Maria Rosa Julià; Odette Viñas; Estíbaliz Ruiz-Ortiz
Journal:  Diagnostics (Basel)       Date:  2022-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.